---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-23-000015"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:47:41.166664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09

## Summary
- Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).
- EYLEA U.S. net sales $1.43B (-6% YoY); Dupixent global net sales $2.49B (+37%, recorded by Sanofi).
- Aflibercept 8 mg BLA accepted for FDA priority review; target action date June 27, 2023 for wet AMD and DME.
- Dupixent Phase 3 COPD trial met endpoints: 30% reduction in exacerbations; first biologic to show benefit in COPD.
- Full-year 2023 guidance: GAAP R&D raised to $4.225-4.465B; GAAP SG&A raised to $2.49-2.68B; gross margin lowered to 87-89%.

## SEC filing metadata
- accession: 0001804220-23-000015
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/0001804220-23-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/regn-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-23-000015
- JSON: https://secwatch.observer/filing/0001804220-23-000015.json
- Plain text: https://secwatch.observer/filing/0001804220-23-000015.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported financial results for the first quarter of 2023.
  - Period: the first quarter of 2023
  - Result: reported results
  source text: On May 4, 2023, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/0001804220-23-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.